AU2012277784B2 - Antibodies against prostate-specific stem cell antigen and use thereof - Google Patents

Antibodies against prostate-specific stem cell antigen and use thereof Download PDF

Info

Publication number
AU2012277784B2
AU2012277784B2 AU2012277784A AU2012277784A AU2012277784B2 AU 2012277784 B2 AU2012277784 B2 AU 2012277784B2 AU 2012277784 A AU2012277784 A AU 2012277784A AU 2012277784 A AU2012277784 A AU 2012277784A AU 2012277784 B2 AU2012277784 B2 AU 2012277784B2
Authority
AU
Australia
Prior art keywords
antibody
seq
psca
antibodies
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012277784A
Other languages
English (en)
Other versions
AU2012277784A1 (en
Inventor
Michael Bachmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avencell Europe GmbH
Original Assignee
Avencell Europe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avencell Europe GmbH filed Critical Avencell Europe GmbH
Publication of AU2012277784A1 publication Critical patent/AU2012277784A1/en
Assigned to GEMOAB MONOCLONALS GMBH reassignment GEMOAB MONOCLONALS GMBH Request for Assignment Assignors: TECHNISCHE UNIVERSITAT DRESDEN
Application granted granted Critical
Publication of AU2012277784B2 publication Critical patent/AU2012277784B2/en
Assigned to GEMoaB GmbH reassignment GEMoaB GmbH Request to Amend Deed and Register Assignors: GEMOAB MONOCLONALS GMBH
Assigned to AVENCELL EUROPE GMBH reassignment AVENCELL EUROPE GMBH Request to Amend Deed and Register Assignors: GEMoaB GmbH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012277784A 2011-06-30 2012-06-29 Antibodies against prostate-specific stem cell antigen and use thereof Ceased AU2012277784B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118022.6 2011-06-30
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Publications (2)

Publication Number Publication Date
AU2012277784A1 AU2012277784A1 (en) 2014-02-06
AU2012277784B2 true AU2012277784B2 (en) 2015-08-20

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012277784A Ceased AU2012277784B2 (en) 2011-06-30 2012-06-29 Antibodies against prostate-specific stem cell antigen and use thereof

Country Status (18)

Country Link
US (1) US9200078B2 (https=)
EP (2) EP3505536B1 (https=)
JP (4) JP2014528696A (https=)
AU (1) AU2012277784B2 (https=)
CY (1) CY1121249T1 (https=)
DE (1) DE102011118022B4 (https=)
DK (1) DK2726507T3 (https=)
ES (2) ES2711978T3 (https=)
HR (1) HRP20190289T1 (https=)
HU (1) HUE042008T2 (https=)
LT (1) LT2726507T (https=)
PL (1) PL2726507T3 (https=)
PT (1) PT2726507T (https=)
RS (1) RS58448B1 (https=)
SI (1) SI2726507T1 (https=)
SM (1) SMT201900085T1 (https=)
TR (1) TR201901991T4 (https=)
WO (1) WO2013001065A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
US20230181772A1 (en) * 2020-05-19 2023-06-15 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005427A1 (en) * 1999-07-20 2001-01-25 The Regents Of The University Of California Psca: prostate stem cell antigen and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0981541B1 (en) * 1997-03-10 2004-06-02 The Regents Of The University Of California Psca: prostate stem cell antigen
ES2309012T3 (es) * 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
MXPA06004035A (es) * 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
NZ551627A (en) * 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005427A1 (en) * 1999-07-20 2001-01-25 The Regents Of The University Of California Psca: prostate stem cell antigen and uses thereof

Also Published As

Publication number Publication date
TR201901991T4 (tr) 2019-03-21
CY1121249T1 (el) 2020-05-29
RS58448B1 (sr) 2019-04-30
JP2014528696A (ja) 2014-10-30
PL2726507T3 (pl) 2019-06-28
US9200078B2 (en) 2015-12-01
JP2019193652A (ja) 2019-11-07
HRP20190289T1 (hr) 2019-05-03
SMT201900085T1 (it) 2019-05-10
JP7341185B2 (ja) 2023-09-08
US20140134155A1 (en) 2014-05-15
EP2726507B1 (de) 2018-11-21
ES2989975T3 (es) 2024-11-28
SI2726507T1 (sl) 2019-05-31
EP3505536C0 (de) 2024-08-07
EP3505536B1 (de) 2024-08-07
EP3505536A1 (de) 2019-07-03
LT2726507T (lt) 2019-04-10
DK2726507T3 (en) 2019-03-11
PT2726507T (pt) 2019-02-26
ES2711978T3 (es) 2019-05-08
JP6549622B2 (ja) 2019-07-24
EP2726507A1 (de) 2014-05-07
DE102011118022B4 (de) 2018-01-18
HUE042008T2 (hu) 2019-06-28
JP6886491B2 (ja) 2021-06-16
AU2012277784A1 (en) 2014-02-06
WO2013001065A1 (de) 2013-01-03
JP2021121201A (ja) 2021-08-26
JP2017104113A (ja) 2017-06-15
DE102011118022A1 (de) 2013-01-03

Similar Documents

Publication Publication Date Title
AU2012277784B2 (en) Antibodies against prostate-specific stem cell antigen and use thereof
JP7642010B2 (ja) 改良された抗原結合受容体
US8759494B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
US11414497B2 (en) Anti-PSMA antibodies and use thereof
KR20220035367A (ko) 항-dll3 키메라 항원 수용체 및 이의 용도
JP2025540716A (ja) Ｐｓｍａ抗体およびその使用
WO2025067496A1 (zh) 靶向baff-r的全人源抗体、car-t细胞及其应用
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
KR20220143904A (ko) 사람 4-1bb 항진제 항체 및 이의 사용 방법
WO2026022767A1 (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
HK40067100A (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof
HK1255107B (en) Antigen binding constructs to target molecules

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GEMOAB MONOCLONALS GMBH

Free format text: FORMER APPLICANT(S): TECHNISCHE UNIVERSITAT DRESDEN

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: GEMOAB GMBH

Free format text: FORMER NAME(S): GEMOAB MONOCLONALS GMBH

HB Alteration of name in register

Owner name: AVENCELL EUROPE GMBH

Free format text: FORMER NAME(S): GEMOAB GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired